JP6345123B2 - 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 - Google Patents
抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 Download PDFInfo
- Publication number
- JP6345123B2 JP6345123B2 JP2014557754A JP2014557754A JP6345123B2 JP 6345123 B2 JP6345123 B2 JP 6345123B2 JP 2014557754 A JP2014557754 A JP 2014557754A JP 2014557754 A JP2014557754 A JP 2014557754A JP 6345123 B2 JP6345123 B2 JP 6345123B2
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- vla
- aqueous pharmaceutical
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 486
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 308
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 142
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 141
- 239000000600 sorbitol Substances 0.000 claims description 141
- 235000010356 sorbitol Nutrition 0.000 claims description 141
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 117
- 229920000053 polysorbate 80 Polymers 0.000 claims description 117
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 115
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 115
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 115
- 229940068977 polysorbate 20 Drugs 0.000 claims description 110
- 238000011282 treatment Methods 0.000 claims description 110
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 105
- 229940068968 polysorbate 80 Drugs 0.000 claims description 105
- 238000003860 storage Methods 0.000 claims description 87
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 81
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 68
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 44
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 43
- 239000003795 chemical substances by application Substances 0.000 claims description 40
- 229920000136 polysorbate Polymers 0.000 claims description 39
- 229950008882 polysorbate Drugs 0.000 claims description 38
- 238000007920 subcutaneous administration Methods 0.000 claims description 36
- 230000004044 response Effects 0.000 claims description 33
- 230000002829 reductive effect Effects 0.000 claims description 31
- 230000002776 aggregation Effects 0.000 claims description 29
- 208000027866 inflammatory disease Diseases 0.000 claims description 29
- 238000004220 aggregation Methods 0.000 claims description 26
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 230000003442 weekly effect Effects 0.000 claims description 13
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 10
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 10
- 229960001743 golimumab Drugs 0.000 claims description 10
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 claims description 10
- 229960004171 hydroxychloroquine Drugs 0.000 claims description 10
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 10
- 229960000681 leflunomide Drugs 0.000 claims description 10
- 229960000485 methotrexate Drugs 0.000 claims description 10
- 229960004641 rituximab Drugs 0.000 claims description 10
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 10
- 229960001940 sulfasalazine Drugs 0.000 claims description 10
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 10
- 108010008165 Etanercept Proteins 0.000 claims description 9
- 229960002964 adalimumab Drugs 0.000 claims description 9
- 229960000403 etanercept Drugs 0.000 claims description 9
- 229960000598 infliximab Drugs 0.000 claims description 9
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims description 8
- 239000003124 biologic agent Substances 0.000 claims description 7
- 229960003115 certolizumab pegol Drugs 0.000 claims description 7
- 208000023275 Autoimmune disease Diseases 0.000 claims description 6
- 239000004012 Tofacitinib Substances 0.000 claims description 6
- 229960003697 abatacept Drugs 0.000 claims description 6
- 208000026278 immune system disease Diseases 0.000 claims description 6
- 229960003989 tocilizumab Drugs 0.000 claims description 6
- 229960001350 tofacitinib Drugs 0.000 claims description 6
- 101710145634 Antigen 1 Proteins 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 3
- 238000013368 capillary electrophoresis sodium dodecyl sulfate analysis Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 description 392
- 238000009472 formulation Methods 0.000 description 222
- 238000000034 method Methods 0.000 description 182
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 139
- 229960002885 histidine Drugs 0.000 description 139
- 229960002920 sorbitol Drugs 0.000 description 139
- 235000014304 histidine Nutrition 0.000 description 137
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 136
- 239000002245 particle Substances 0.000 description 120
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 111
- 239000000523 sample Substances 0.000 description 104
- 125000000539 amino acid group Chemical group 0.000 description 83
- 108090000623 proteins and genes Proteins 0.000 description 83
- 239000000872 buffer Substances 0.000 description 81
- 102000004169 proteins and genes Human genes 0.000 description 69
- 235000018102 proteins Nutrition 0.000 description 68
- 235000002639 sodium chloride Nutrition 0.000 description 67
- 235000001014 amino acid Nutrition 0.000 description 62
- 229940024606 amino acid Drugs 0.000 description 57
- 239000002552 dosage form Substances 0.000 description 56
- 238000013456 study Methods 0.000 description 56
- 102100025323 Integrin alpha-1 Human genes 0.000 description 55
- 108010041341 Integrin alpha1 Proteins 0.000 description 55
- 239000011780 sodium chloride Substances 0.000 description 55
- 108010055795 Integrin alpha1beta1 Proteins 0.000 description 54
- 150000001413 amino acids Chemical group 0.000 description 50
- 239000003814 drug Substances 0.000 description 47
- 239000004094 surface-active agent Substances 0.000 description 40
- 208000024891 symptom Diseases 0.000 description 39
- 230000037396 body weight Effects 0.000 description 36
- 206010003246 arthritis Diseases 0.000 description 33
- 230000001186 cumulative effect Effects 0.000 description 32
- 239000007924 injection Substances 0.000 description 32
- 238000002347 injection Methods 0.000 description 32
- 238000004458 analytical method Methods 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 230000027455 binding Effects 0.000 description 29
- 239000012634 fragment Substances 0.000 description 29
- 239000000546 pharmaceutical excipient Substances 0.000 description 27
- 239000000463 material Substances 0.000 description 26
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 24
- 229940124597 therapeutic agent Drugs 0.000 description 24
- 230000006872 improvement Effects 0.000 description 23
- 208000035475 disorder Diseases 0.000 description 22
- 238000002296 dynamic light scattering Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 239000000126 substance Substances 0.000 description 22
- 239000003112 inhibitor Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 238000012360 testing method Methods 0.000 description 20
- 229940079593 drug Drugs 0.000 description 19
- 210000001503 joint Anatomy 0.000 description 19
- 239000012669 liquid formulation Substances 0.000 description 19
- 239000008351 acetate buffer Substances 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 18
- 230000008569 process Effects 0.000 description 18
- 238000013467 fragmentation Methods 0.000 description 17
- 238000006062 fragmentation reaction Methods 0.000 description 17
- 229910052700 potassium Inorganic materials 0.000 description 17
- 230000035882 stress Effects 0.000 description 17
- 238000005259 measurement Methods 0.000 description 15
- 206010023232 Joint swelling Diseases 0.000 description 14
- 238000001802 infusion Methods 0.000 description 14
- 102000008186 Collagen Human genes 0.000 description 13
- 108010035532 Collagen Proteins 0.000 description 13
- 108060003951 Immunoglobulin Proteins 0.000 description 13
- 229920001436 collagen Polymers 0.000 description 13
- 102000018358 immunoglobulin Human genes 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 13
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 12
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 12
- 206010052779 Transplant rejections Diseases 0.000 description 12
- 238000013019 agitation Methods 0.000 description 12
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000005277 cation exchange chromatography Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 229910052740 iodine Inorganic materials 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 12
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 11
- 201000004681 Psoriasis Diseases 0.000 description 11
- -1 analgesic Substances 0.000 description 11
- 239000013011 aqueous formulation Substances 0.000 description 11
- 230000006378 damage Effects 0.000 description 11
- 239000000499 gel Substances 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 239000000178 monomer Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 239000012925 reference material Substances 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 10
- 230000000875 corresponding effect Effects 0.000 description 10
- 239000003246 corticosteroid Substances 0.000 description 10
- 238000009295 crossflow filtration Methods 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 10
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 108010016672 Syk Kinase Proteins 0.000 description 9
- 102100038183 Tyrosine-protein kinase SYK Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000000113 differential scanning calorimetry Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000012491 analyte Substances 0.000 description 8
- 238000009093 first-line therapy Methods 0.000 description 8
- 239000012537 formulation buffer Substances 0.000 description 8
- 230000002757 inflammatory effect Effects 0.000 description 8
- 102000006495 integrins Human genes 0.000 description 8
- 108010044426 integrins Proteins 0.000 description 8
- 206010025135 lupus erythematosus Diseases 0.000 description 8
- 239000013618 particulate matter Substances 0.000 description 8
- 238000004611 spectroscopical analysis Methods 0.000 description 8
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 7
- 108010074051 C-Reactive Protein Proteins 0.000 description 7
- 102100032752 C-reactive protein Human genes 0.000 description 7
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 7
- 230000001387 anti-histamine Effects 0.000 description 7
- 239000000739 antihistaminic agent Substances 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 230000009266 disease activity Effects 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 208000018937 joint inflammation Diseases 0.000 description 7
- 150000007523 nucleic acids Chemical class 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 101001078158 Homo sapiens Integrin alpha-1 Proteins 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000013401 experimental design Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000012495 forced degradation study Methods 0.000 description 6
- 238000012395 formulation development Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 230000004048 modification Effects 0.000 description 6
- 238000012986 modification Methods 0.000 description 6
- 229960005489 paracetamol Drugs 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000012546 transfer Methods 0.000 description 6
- 239000004475 Arginine Substances 0.000 description 5
- 208000003456 Juvenile Arthritis Diseases 0.000 description 5
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
- 230000002917 arthritic effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000005388 borosilicate glass Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 229960004584 methylprednisolone Drugs 0.000 description 5
- 230000036542 oxidative stress Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 229940071643 prefilled syringe Drugs 0.000 description 5
- 239000012088 reference solution Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 5
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 108010024121 Janus Kinases Proteins 0.000 description 4
- 102000015617 Janus Kinases Human genes 0.000 description 4
- 102100028793 Mucosal addressin cell adhesion molecule 1 Human genes 0.000 description 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 description 4
- 239000002260 anti-inflammatory agent Substances 0.000 description 4
- 238000000149 argon plasma sintering Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000003628 erosive effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 201000000306 sarcoidosis Diseases 0.000 description 4
- 238000009094 second-line therapy Methods 0.000 description 4
- 201000004595 synovitis Diseases 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010071155 Autoimmune arthritis Diseases 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 3
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 3
- 239000002033 PVDF binder Substances 0.000 description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 229920005556 chlorobutyl Polymers 0.000 description 3
- 238000002983 circular dichroism Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000006240 deamidation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000009851 immunogenic response Effects 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229910021645 metal ion Inorganic materials 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000013558 reference substance Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012496 stress study Methods 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 229960004914 vedolizumab Drugs 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 2
- 108010017642 Integrin alpha2beta1 Proteins 0.000 description 2
- 238000012773 Laboratory assay Methods 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000020410 Psoriasis-related juvenile idiopathic arthritis Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 2
- 206010047642 Vitiligo Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000009118 appropriate response Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000000779 depleting effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000012538 diafiltration buffer Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 230000008642 heat stress Effects 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 239000007925 intracardiac injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000004990 juvenile ankylosing spondylitis Diseases 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 201000008265 mesangial proliferative glomerulonephritis Diseases 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012465 retentate Substances 0.000 description 2
- 238000010008 shearing Methods 0.000 description 2
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 238000012430 stability testing Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000011123 type I (borosilicate glass) Substances 0.000 description 2
- CMXXUDSWGMGYLZ-XRIGFGBMSA-N (2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)[C@@H](N)CC1=CN=CN1 CMXXUDSWGMGYLZ-XRIGFGBMSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- CMXXUDSWGMGYLZ-UHFFFAOYSA-N 2-amino-3-(1h-imidazol-5-yl)propanoic acid;hydron;chloride;hydrate Chemical compound O.Cl.OC(=O)C(N)CC1=CN=CN1 CMXXUDSWGMGYLZ-UHFFFAOYSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- YUPRHHFLOLUPFG-UHFFFAOYSA-N Alkaloid AQC2 Chemical compound C1C(CC)(CC2)CN=C(O)C1OC(=O)CC1=C2NC2=CC=CC=C12 YUPRHHFLOLUPFG-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010051763 Bone marrow oedema Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 229930195721 D-histidine Natural products 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101001059662 Homo sapiens Mucosal addressin cell adhesion molecule 1 Proteins 0.000 description 1
- 101000607909 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 1 Proteins 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- 206010022086 Injection site pain Diseases 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 102000042838 JAK family Human genes 0.000 description 1
- 108091082332 JAK family Proteins 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 229940121730 Janus kinase 2 inhibitor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 206010028703 Nail psoriasis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 108010010057 TYK2 Kinase Proteins 0.000 description 1
- 102000015774 TYK2 Kinase Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 229940123371 Tyrosine kinase 2 inhibitor Drugs 0.000 description 1
- 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 1
- 102100039865 Ubiquitin carboxyl-terminal hydrolase 1 Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003432 anti-folate effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940127074 antifolate Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000035289 cell-matrix adhesion Effects 0.000 description 1
- 210000003570 cell-matrix junction Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012468 concentrated sample Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011035 continuous diafiltration Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002310 elbow joint Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 230000009795 fibrotic process Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 239000013016 formulated drug substance Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 238000013457 freeze/thaw-study Methods 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 210000000811 metacarpophalangeal joint Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940090048 pen injector Drugs 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 201000002793 renal fibrosis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000011519 second-line treatment Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000323 shoulder joint Anatomy 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013097 stability assessment Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 210000001226 toe joint Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- KYWVDGFGRYJLPE-UHFFFAOYSA-N trimethylazanium;acetate Chemical compound CN(C)C.CC(O)=O KYWVDGFGRYJLPE-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000003857 wrist joint Anatomy 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261599827P | 2012-02-16 | 2012-02-16 | |
| US61/599,827 | 2012-02-16 | ||
| PCT/US2013/026034 WO2013123114A2 (en) | 2012-02-16 | 2013-02-14 | Antibody formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097486A Division JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508774A JP2015508774A (ja) | 2015-03-23 |
| JP2015508774A5 JP2015508774A5 (enExample) | 2016-03-24 |
| JP6345123B2 true JP6345123B2 (ja) | 2018-06-20 |
Family
ID=47997774
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557754A Expired - Fee Related JP6345123B2 (ja) | 2012-02-16 | 2013-02-14 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
| JP2018097486A Active JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018097486A Active JP6759276B2 (ja) | 2012-02-16 | 2018-05-22 | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (5) | US10316095B2 (enExample) |
| EP (1) | EP2814468B1 (enExample) |
| JP (2) | JP6345123B2 (enExample) |
| CN (1) | CN104271122A (enExample) |
| AU (2) | AU2013221635B2 (enExample) |
| CA (1) | CA2864539C (enExample) |
| ES (1) | ES2732243T3 (enExample) |
| IL (1) | IL233976B (enExample) |
| MX (1) | MX370199B (enExample) |
| NZ (1) | NZ629204A (enExample) |
| WO (1) | WO2013123114A2 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018138614A (ja) * | 2012-02-16 | 2018-09-06 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2557768T3 (es) | 1999-06-01 | 2016-01-28 | Biogen Ma Inc. | Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios |
| KR100927670B1 (ko) | 2001-04-13 | 2009-11-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｖｌａ-1에 대한 항체들 |
| PL3459564T3 (pl) | 2010-01-06 | 2022-04-19 | Takeda Pharmaceutical Company Limited | Białka wiążące kalikreinę osocza |
| KR102502293B1 (ko) | 2011-01-06 | 2023-02-21 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 |
| TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗ｍｃａｍ抗體及相關使用方法 |
| EP3594244A1 (en) | 2013-03-15 | 2020-01-15 | Dyax Corp. | Anti-plasma kallikrein antibodies |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| KR20220107077A (ko) | 2014-01-21 | 2022-08-01 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 결합 단백질 및 유전성 혈관부종을 치료하는 데 있어서의 이의 용도 |
| PT3116911T (pt) | 2014-03-12 | 2019-09-04 | Prothena Biosciences Ltd | Anticorpos anti-mcam e métodos de utilização associados |
| WO2015136472A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| EP3122782A4 (en) | 2014-03-27 | 2017-09-13 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| JP2017531446A (ja) * | 2014-09-29 | 2017-10-26 | クック・ジェネラル・バイオテクノロジー・エルエルシー | 細胞懸濁液中のトレハロースの使用 |
| MX391067B (es) | 2014-10-01 | 2025-03-21 | Eagle Biologics Inc | Formulaciones de polisacáridos y ácido nucleico que contienen agentes de reducción de viscosidad. |
| US20160367180A1 (en) * | 2015-06-17 | 2016-12-22 | Obsevera, Inc. | Apparatus and method of conducting medical evaluation of add/adhd |
| CA2998716A1 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| KR20250139401A (ko) | 2015-12-11 | 2025-09-23 | 다케다 파머수티컬 컴패니 리미티드 | 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도 |
| MX2018011169A (es) * | 2016-03-14 | 2018-12-06 | Millennium Pharm Inc | Metodo para prevenir la enfermedad del injerto contra huesped. |
| BR112018075785A2 (pt) * | 2016-06-16 | 2019-04-02 | Janssen Vaccines & Prevention B.V. | formulação de vacina para o hiv |
| CR20180599A (es) * | 2016-06-30 | 2019-04-09 | Celltrion Inc | Preparación farmacéutica líquida estable |
| WO2019018688A1 (en) * | 2017-07-20 | 2019-01-24 | The University Of Virginia Patent Foundation | METHODS OF TREATING OR PREVENTING A NEUROLOGICAL DISORDER OF THE IMMUNE SYSTEM |
| CN112236445A (zh) * | 2017-12-14 | 2021-01-15 | 芝加哥大学 | 用基因工程化的巨噬细胞治疗纤维化 |
| CN111787948A (zh) * | 2018-02-09 | 2020-10-16 | 健玛保 | 包含针对cd3和cd20的双特异性抗体的药物组合物及其用途 |
| EP3911363A1 (en) * | 2019-01-14 | 2021-11-24 | University of Virginia Patent Foundation | Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury |
| MA55750A (fr) * | 2019-04-23 | 2022-03-02 | Sanofi Sa | Formulations d'anticorps stables et à faible viscosité et leurs utilisations |
| UA128416C2 (uk) * | 2019-08-15 | 2024-07-03 | Генмаб А/С | Фармацевтичні композиції, які містять біспецифічні антитіла проти cd3 і cd20, та їх застосування |
| CA3167336A1 (en) | 2020-01-13 | 2021-07-22 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack |
| CN115916166A (zh) | 2020-05-08 | 2023-04-04 | 健玛保 | 针对cd3和cd20的双特异性抗体 |
| JP2023542289A (ja) | 2020-09-10 | 2023-10-06 | ジェンマブ エー／エス | 濾胞性リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| WO2022053654A1 (en) | 2020-09-10 | 2022-03-17 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| MX2023002544A (es) | 2020-09-10 | 2023-03-14 | Genmab As | Anticuerpo biespecifico contra cumulo de diferenciacion 3 (cd3) y cumulo de diferenciacion 20 (cd20) en terapia de combinacion para tratar linfoma folicular. |
| EP4210744A1 (en) | 2020-09-10 | 2023-07-19 | Genmab A/S | Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma |
| AU2021342342A1 (en) | 2020-09-10 | 2023-04-13 | Genmab A/S | Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia |
| CA3218343A1 (en) * | 2021-05-12 | 2022-11-17 | Anaptysbio, Inc. | Antibody composition |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5391481A (en) | 1990-08-31 | 1995-02-21 | The Trustees Of Columbia University | Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof |
| US5871907A (en) | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| CA2127462C (en) | 1992-01-13 | 1999-03-23 | Roy R. Lobb | Treatment for asthma |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US6307026B1 (en) | 1992-12-10 | 2001-10-23 | Celltech Limited | Humanized antibodies directed against A33 antigen |
| EP0678122B1 (en) | 1993-01-12 | 1999-07-28 | Biogen, Inc. | Recombinant anti-vla4 antibody molecules |
| ES2114183T5 (es) | 1993-02-09 | 2006-06-16 | Biogen Idec Ma, Inc. | Anticuerpo para el tratamiento de la diabetes dependiente de la insulina. |
| US6111598A (en) | 1993-11-12 | 2000-08-29 | Peveo, Inc. | System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| PT804237E (pt) | 1994-01-25 | 2006-10-31 | Elan Pharm Inc | Anticorpos humanizados contra a molecula de adesao leucocitaria vla-4 |
| DK0759302T3 (da) | 1994-04-26 | 2000-11-13 | Kanebo Ltd | Middel mod rheumatoid arthritis |
| JPH08131185A (ja) | 1994-11-14 | 1996-05-28 | Sumitomo Electric Ind Ltd | マウスｖｌａ−１分子に対するモノクローナル抗体 |
| JPH08160972A (ja) | 1994-12-01 | 1996-06-21 | Sega Enterp Ltd | エフェクト制御方法、制御装置およびこれを利用したカラオケ装置 |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9516399D0 (en) | 1995-08-10 | 1995-10-11 | Camelot Superabsorbents Ltd | Process for the production of water-absorbing compositions |
| DK1143006T3 (da) | 1995-08-18 | 2008-07-14 | Morphosys Ip Gmbh | Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker |
| WO1997007671A1 (en) | 1995-08-29 | 1997-03-06 | Kirin Beer Kabushiki Kaisha | Chimeric animal and method for constructing the same |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| GB9519667D0 (en) | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
| DE19541844C1 (de) | 1995-11-09 | 1997-07-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung |
| US6127524A (en) | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| EP0999853B1 (en) * | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
| JP2002516287A (ja) | 1998-05-22 | 2002-06-04 | ボーイズ タウン ナショナル リサーチ ホスピタル | α１β１インテグリンレセプターインヒビターおよびＩＧＦ−β１インヒビターの腎臓病の治療における使用 |
| DE19831710A1 (de) | 1998-07-15 | 2000-01-20 | Merck Patent Gmbh | Diacylhydrazinderivate |
| AU751157B2 (en) | 1998-10-06 | 2002-08-08 | Biogen Idec Ma Inc. | Crystals of the alpha 1 beta 1 integrin I-domain and their use |
| TR200200027T2 (tr) | 1999-04-22 | 2002-07-22 | Biogen, Inc. | İntergrin alfa-4 alt-biriminin bir antagonisti kullanılarak fibrozun tedavisi. |
| ES2557768T3 (es) | 1999-06-01 | 2016-01-28 | Biogen Ma Inc. | Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios |
| WO2000078221A1 (de) | 1999-06-17 | 2000-12-28 | Kai Desinger | Chirurgische sonde zur minimal invasiven gewebeentnahme |
| WO2001073444A2 (en) | 2000-03-28 | 2001-10-04 | Cambridge University Technical Services Limited | Receptor/peptide crystal structure for identification of inhibitors |
| US8288322B2 (en) | 2000-04-17 | 2012-10-16 | Dyax Corp. | Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries |
| DE10028402A1 (de) | 2000-06-13 | 2001-12-20 | Merck Patent Gmbh | Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate |
| US7153944B2 (en) | 2000-07-31 | 2006-12-26 | The General Hospital Corporation | High affinity integrin polypeptides and uses thereof |
| KR100927670B1 (ko) | 2001-04-13 | 2009-11-20 | 바이오겐 아이덱 엠에이 인코포레이티드 | Ｖｌａ-1에 대한 항체들 |
| IL161677A0 (en) * | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| AU2003215298A1 (en) | 2002-02-14 | 2003-09-04 | Biogen, Inc. | Alpha1beta1 antagonists for treatment of atherosclerosis |
| CA2494310A1 (en) | 2002-08-01 | 2004-02-12 | Immunomedics, Inc. | Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof |
| US20040208870A1 (en) * | 2003-01-30 | 2004-10-21 | Medimmune, Inc. | Stabilized high concentration anti-integrin alphanubeta3 antibody formulations |
| CA2512174A1 (en) * | 2003-01-30 | 2004-08-12 | Christian B. Allan | Anti-integrin .alpha..nu..beta.3 antibody formulations and uses thereof |
| WO2005019200A2 (en) | 2003-08-14 | 2005-03-03 | Icos Corporation | Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof |
| WO2005016883A2 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Acrylamide derivatives as vla-1 integrin antagonists and uses thereof |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| WO2006124269A2 (en) | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2006133286A2 (en) | 2005-06-07 | 2006-12-14 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Treatment of tnf antagonist-resistant inflammatory disorders and related methods |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| US20080118496A1 (en) | 2006-04-10 | 2008-05-22 | Medich John R | Uses and compositions for treatment of juvenile rheumatoid arthritis |
| US9283260B2 (en) | 2006-04-21 | 2016-03-15 | Amgen Inc. | Lyophilized therapeutic peptibody formulations |
| US10119979B2 (en) * | 2006-05-25 | 2018-11-06 | Biogen Ma Inc. | Methods of treating stroke and traumatic brain injury using humanized AQC2 anti-VLA-1 antibodies |
| US7626243B2 (en) | 2006-08-04 | 2009-12-01 | Advanced Analogic Technologies, Inc. | ESD protection for bipolar-CMOS-DMOS integrated circuit devices |
| EP2170390B1 (en) * | 2007-06-14 | 2018-11-07 | Biogen MA Inc. | Natalizumab antibody formulations |
| JP4951596B2 (ja) | 2008-07-31 | 2012-06-13 | 株式会社日立製作所 | 冷却システム及び電子装置 |
| CN102202655B (zh) * | 2008-08-27 | 2013-06-19 | 默沙东公司 | 基因工程抗IL-23p19抗体的冻干制剂 |
| EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
| AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
| CN102770158B (zh) * | 2009-12-21 | 2016-10-19 | 霍夫曼-拉罗奇有限公司 | 抗体配制剂 |
| CA2794929C (en) * | 2010-03-01 | 2018-06-05 | Progenics Pharmaceuticals, Inc. | Concentrated protein formulations and uses thereof |
| AU2011257219B2 (en) * | 2010-05-28 | 2014-12-04 | Novo Nordisk A/S | Stable multi-dose compositions comprising an antibody and a preservative |
| US20140017261A1 (en) | 2011-02-03 | 2014-01-16 | Mark Totoritis | Selection and treatment of subjects |
| JP5662565B2 (ja) | 2012-01-11 | 2015-02-04 | パナソニックＩｐマネジメント株式会社 | 圧接型半導体装置及びその製造方法 |
| US10316095B2 (en) | 2012-02-16 | 2019-06-11 | Santarus, Inc. | Antibody formulations |
-
2013
- 2013-02-14 US US13/766,966 patent/US10316095B2/en active Active
- 2013-02-14 US US14/379,095 patent/US10160808B2/en active Active
- 2013-02-14 ES ES13711986T patent/ES2732243T3/es active Active
- 2013-02-14 MX MX2014009755A patent/MX370199B/es active IP Right Grant
- 2013-02-14 JP JP2014557754A patent/JP6345123B2/ja not_active Expired - Fee Related
- 2013-02-14 NZ NZ629204A patent/NZ629204A/en not_active IP Right Cessation
- 2013-02-14 CA CA2864539A patent/CA2864539C/en active Active
- 2013-02-14 CN CN201380019988.XA patent/CN104271122A/zh active Pending
- 2013-02-14 AU AU2013221635A patent/AU2013221635B2/en not_active Ceased
- 2013-02-14 EP EP13711986.3A patent/EP2814468B1/en active Active
- 2013-02-14 WO PCT/US2013/026034 patent/WO2013123114A2/en not_active Ceased
- 2013-08-30 US US14/015,039 patent/US20140010827A1/en not_active Abandoned
-
2014
- 2014-08-06 IL IL233976A patent/IL233976B/en active IP Right Grant
-
2017
- 2017-11-22 AU AU2017265049A patent/AU2017265049B2/en not_active Ceased
-
2018
- 2018-05-22 JP JP2018097486A patent/JP6759276B2/ja active Active
- 2018-12-20 US US16/227,564 patent/US20190194331A1/en not_active Abandoned
-
2019
- 2019-04-24 US US16/393,171 patent/US20190338036A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018138614A (ja) * | 2012-02-16 | 2018-09-06 | サンタラス， インコーポレイテッド | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013221635A1 (en) | 2014-09-18 |
| WO2013123114A2 (en) | 2013-08-22 |
| AU2013221635A2 (en) | 2014-12-11 |
| JP6759276B2 (ja) | 2020-09-23 |
| JP2015508774A (ja) | 2015-03-23 |
| EP2814468B1 (en) | 2019-06-19 |
| MX370199B (es) | 2019-12-05 |
| ES2732243T3 (es) | 2019-11-21 |
| US20140010827A1 (en) | 2014-01-09 |
| US20190338036A1 (en) | 2019-11-07 |
| MX2014009755A (es) | 2015-02-24 |
| EP2814468A2 (en) | 2014-12-24 |
| CA2864539C (en) | 2022-06-07 |
| AU2017265049A1 (en) | 2017-12-14 |
| US20130216556A1 (en) | 2013-08-22 |
| CA2864539A1 (en) | 2013-08-22 |
| US10160808B2 (en) | 2018-12-25 |
| IL233976A0 (en) | 2014-09-30 |
| JP2018138614A (ja) | 2018-09-06 |
| AU2017265049B2 (en) | 2019-10-24 |
| US20190194331A1 (en) | 2019-06-27 |
| HK1199620A1 (en) | 2015-07-10 |
| US20160017043A1 (en) | 2016-01-21 |
| US10316095B2 (en) | 2019-06-11 |
| NZ629204A (en) | 2016-09-30 |
| WO2013123114A3 (en) | 2013-12-05 |
| IL233976B (en) | 2018-08-30 |
| CN104271122A (zh) | 2015-01-07 |
| AU2013221635B2 (en) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6345123B2 (ja) | 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物 | |
| JP7277649B2 (ja) | 高濃度抗ｃ５抗体製剤 | |
| TWI614028B (zh) | 抗體調配物 | |
| JP2021152021A (ja) | 乾癬性関節炎患者における構造的損傷の進行を阻害するためのｉｌ−１７アンタゴニストの使用 | |
| CN107252483A (zh) | 受试者的选择和治疗 | |
| US20240409631A1 (en) | Aqueous formulations of an anti-cd22 antibody and uses thereof | |
| HK1199620B (en) | Anti-vla1 (cd49a) antibody pharmaceutical compositions | |
| KR20230026407A (ko) | 액티빈 a 항체 제형 및 이의 사용 방법 | |
| HK40006379A (en) | Natalizumab antibody formulations | |
| HK1143060A (en) | Natalizumab antibody formulations | |
| HK1143060B (en) | Natalizumab antibody formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160202 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160202 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161014 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170106 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170106 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170113 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170106 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170414 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170704 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170928 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171228 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180424 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180522 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6345123 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |